What is the level of liabilities of MannKind this year?
MannKind has a debt balance of 721.37 M USD this year.
MannKind Liabilities 2024
MannKind Liabilities
721.37 M USD
Ticker
MNKD
ISIN
US56400P7069
WKN
A2DMZL
In 2024, MannKind's total liabilities amounted to 721.37 M USD, a 32.17% difference from the 545.8 M USD total liabilities in the previous year.
MannKind Aktienanalyse
What does MannKind do?
MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing MannKind's Liabilities
MannKind's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating MannKind's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing MannKind's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
MannKind's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in MannKind’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about MannKind stock
What were the liabilities of MannKind compared to the previous year?
The liabilities of MannKind have increased by 32.17% increased compared to the previous year.
What are the consequences of high debt for investors of MannKind?
High liabilities can pose a risk for investors of MannKind, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in MannKind?
Low liabilities mean that MannKind has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of MannKind affect the company?
An increase in liabilities of MannKind can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of MannKind affect the company?
A decrease in the liabilities of MannKind can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of MannKind?
Some factors that can influence the liabilities of MannKind include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of MannKind so important for investors?
The liabilities of MannKind are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can MannKind take to modify the liabilities?
To change its liabilities, MannKind can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does MannKind pay?
Over the past 12 months, MannKind paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MannKind is expected to pay a dividend of 0 USD.
What is the dividend yield of MannKind?
The current dividend yield of MannKind is .
When does MannKind pay dividends?
MannKind pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MannKind?
MannKind paid dividends every year for the past 0 years.
What is the dividend of MannKind?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MannKind located?
MannKind is assigned to the 'Health' sector.
Wann musste ich die Aktien von MannKind kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MannKind from 8/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/28/2024.
When did MannKind pay the last dividend?
The last dividend was paid out on 8/28/2024.
What was the dividend of MannKind in the year 2023?
In the year 2023, MannKind distributed 0 USD as dividends.
In which currency does MannKind pay out the dividend?
The dividends of MannKind are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The MannKind stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von MannKind
Our stock analysis for MannKind Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MannKind Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
